Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report
- PMID: 36051149
- PMCID: PMC9297397
- DOI: 10.12998/wjcc.v10.i20.7124
Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report
Abstract
Background: Immune checkpoint inhibitors have significantly improved survivals for an increasing range of malignancies but at the cost of several immune-related adverse events, the management of which can be challenging due to its mimicry of other autoimmune related disorders such as immunoglobulin G4 (IgG4) related disease when the pancreaticobiliary system is affected. Nivolumab, an IgG4 monoclonal antibody, has been associated with cholangitis and pancreatitis, however its association with IgG4 related disease has not been reported to date.
Case summary: We present a case of immune-related pancreatitis and cholangiopathy in a patient who completed treatment with nivolumab for anal squamous cell carcinoma. Patients IgG4 levels was normal on presentation. She responded to steroids but due to concerns for malignant biliary stricture, she opted for surgery, the pathology of which suggested IgG4 related disease.
Conclusion: We hypothesize this case of IgG4 related cholangitis and pancreatitis was likely triggered by nivolumab.
Keywords: Biliary stricture; Case report; Cholangitis; Immunoglobulin G4 related disease; Nivolumab; Pancreatitis.
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Figures


Similar articles
-
[Immunoglobulin G4-related disease in gastroenterology].Vnitr Lek. 2021 Spring;67(2):76-83. Vnitr Lek. 2021. PMID: 34074105 Czech.
-
Immunoglobulin G4-Seronegative Autoimmune Cholangiopathy With Pancreatic and Hepatic Involvement Mimicking as Primary Sclerosing Cholangitis.ACG Case Rep J. 2023 Apr 20;10(4):e01044. doi: 10.14309/crj.0000000000001044. eCollection 2023 Apr. ACG Case Rep J. 2023. PMID: 37091206 Free PMC article.
-
IgG4-Related Cholangiopathy and Its Mimickers: A Case Report and Review Highlighting the Importance of Early Diagnosis.Int J Surg Pathol. 2018 Apr;26(2):165-173. doi: 10.1177/1066896917730902. Epub 2017 Sep 14. Int J Surg Pathol. 2018. PMID: 28905689 Review.
-
Immunoglobulin G4-related sclerosing cholangitis.Korean J Intern Med. 2018 Sep;33(5):841-850. doi: 10.3904/kjim.2018.018. Epub 2018 Jul 27. Korean J Intern Med. 2018. PMID: 30045615 Free PMC article. Review.
-
Sequential Evaluation of Pancreato-Biliary Findings in a Case with IgG4-Associated Cholangiopathy and Autoimmune Pancreatitis during Corticosteroid Treatment.Balkan Med J. 2016 Jul;33(4):458-61. doi: 10.5152/balkanmedj.2016.15420. Epub 2016 Jul 1. Balkan Med J. 2016. PMID: 27606144 Free PMC article.
Cited by
-
Secondary sclerosing cholangitis and IgG4-sclerosing cholangitis - A review of cholangiographic and ultrasound imaging.Endosc Ultrasound. 2023 Mar-Apr;12(2):181-199. doi: 10.4103/EUS-D-22-00208. Endosc Ultrasound. 2023. PMID: 36588352 Free PMC article. Review.
-
Immune Checkpoint Inhibitor-induced Pancreatitis with Pancreatic Enlargement Mimicking Autoimmune Pancreatitis: A Case Report and Review of the Literature.Intern Med. 2024 Mar 15;63(6):791-798. doi: 10.2169/internalmedicine.1943-23. Epub 2023 Aug 2. Intern Med. 2024. PMID: 37532549 Free PMC article. Review.
-
Immunoglobulin G4-related Autoimmune Pancreatitis and Hypopituitarism Following Immune Checkpoint Inhibitor Therapy.Intern Med. 2025 Jan 15;64(2):209-215. doi: 10.2169/internalmedicine.3591-24. Epub 2024 May 30. Intern Med. 2025. PMID: 38811225 Free PMC article.
-
Retrospective analysis of clinical features of nivolumab-induced immune-related pancreatitis.Invest New Drugs. 2025 Apr;43(2):276-283. doi: 10.1007/s10637-025-01517-8. Epub 2025 Feb 24. Invest New Drugs. 2025. PMID: 39994086
-
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort.JHEP Rep. 2023 Mar 7;5(6):100719. doi: 10.1016/j.jhepr.2023.100719. eCollection 2023 Jun. JHEP Rep. 2023. PMID: 37138674 Free PMC article.
References
-
- Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. 2021;16:223–249. - PubMed
-
- Thanarajasingam U, Abdel-Wahab N. Immune Checkpoint Inhibition-Does It Cause Rheumatic Diseases? Rheum Dis Clin North Am. 2020;46:587–603. - PubMed
-
- Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378:158–168. - PubMed
-
- Radulescu L, Crisan D, Grapa C, Radulescu D. Digestive Toxicities Secondary to Immune Checkpoint Inhibition Therapy - Reports of Rare Events. A Systematic Review. J Gastrointestin Liver Dis. 2021;30:506–516. - PubMed
Publication types
LinkOut - more resources
Full Text Sources